Title
Analysis of the RPGR gene in 11 pedigrees with the retinitis pigmentosa type 3 genotype: Paucity of mutations in the coding region but splice defects in two families
Date Issued
01 September 1997
Access level
open access
Resource Type
journal article
Author(s)
Buraczynska M.
Gieser L.
Wu W.
Forsythe P.
Abrahamson M.
Jacobson S.
Sieving P.
Andréasson S.
Swaroop A.
University of Michigan
Publisher(s)
Cell Press
Abstract
X-linked retinitis pigmentosa (XLRP) is a severe form of inherited progressive retinal degeneration. The RP3 (retinitis pigmentosa type 3) locus at Xp21.1 is believed to account for the disease in the majority of XLRP families. Linkage analysis and identification of patients with chromosomal deletion have refined the location of the RP3 locus and recently have led to the cloning of the RPGR (retinitis pigmentosa GTPase regulator) gene, which has been shown to be mutated in 10%-15% of XLRP patients. In order to systematically characterize the RPGR mutations, we identified 11 retinitis pigmentosa type III (RP3) families by haplotype analysis. Sequence analysis of the PCR-amplified genomic DNA from patients representing these RP3 families did not reveal any causative mutation in RPGR exons 2-19, spanning >98% of the coding region. In patients from two families, we identified transition mutations in the intron region near splice sites [IVS10+3 and IVS13-8). RNA analysis showed that both splice-site mutations resulted in the generation of aberrant RPGR transcripts. Our results support the hypothesis that mutations in the reported RPGR gene are not a common defect in the RP3 subtype of XLRP and that a majority of causative mutations may reside either in as yet unidentified RPGR exons or in another nearby gene at Xp21.1.
Start page
571
End page
580
Volume
61
Issue
3
Language
English
OCDE Knowledge area
Genética humana
Scopus EID
2-s2.0-16944362660
PubMed ID
Source
American Journal of Human Genetics
ISSN of the container
00029297
Sponsor(s)
We are grateful to the XLRP patients and their family members who participated in the study. We thank Dr. Kirk Alek and Ms. Gina Osland for collecting data on family XLRP-112, Ms. Kinga Buraczynska for technical assistance, and Drs. Jean Bennett, Gerald Fishman, Jacquie Greenberg, and Dennis Hoffman for XLRP families that they provided for our ongoing investigations but that are not included in this study. This work was supported by National Institutes of Health (NIH) grants EY07961 (to A.S.) and EY05627 (to S.G.J.), by a grant from The Foundation Fighting Blindness (to S.G.J., P.A.S., and A.S.), by a grant from The Chatlos Foundation (S.G.J.), and by a grant from Research to Prevent Blindness. We also acknowledge NIH grants EY07003 (Core) and M01-RR00042 (General Clinical Research Center).
Sources of information: Directorio de Producción Científica Scopus